16:14 IST
BSE
Employee Stock Options
Lupin Employee Stock Options
Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.
Lupin Ltd
- Share price
- ₹2,092.00
- Market cap
- ₹95,665 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.3×Sector 50.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
17:38 IST
NSE
Product Launch
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
21:30 IST
BSE
Earnings Call
Lupin Earnings Call Transcript: Key Takeaways
Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.
22:12 IST
NSE
Earnings Call
Lupin Investor Presentation: Key Takeaways
Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.
22:04 IST
NSE
Financial Results
Lupin Q1 FY27 Results: Net Profit ₹1,415 Cr, Up 16.1% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,415 Cr (+16.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,415 Cr · +16.1% YoY
21:54 IST
NSE
Financial Results
Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,417 Cr · +16.0% YoY
17:09 IST
NSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.
21:22 IST
NSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin delivered a record-breaking FY26 with 32% revenue growth and 68% EBITDA surge, driven by US generic exclusivity and robust India prescription growth.
21:43 IST
BSE
Earnings Call
Lupin Earnings Call: Key Takeaways
Lupin reported strong Q4 FY26 results with sales reaching ₹73,919 mn, up 33% YoY, driven by a 55% surge in North American markets.
20:51 IST
BSE
Financial Results
Lupin Q4 FY26 Results: Net Profit ₹1,469 Cr, Up 87.7% YoY
Lupin Ltd reported revenue from operations of ₹7,475 Cr (+31.9% YoY) and net profit of ₹1,469 Cr (+87.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹1,469 Cr · +87.7% YoY